Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Recurrence 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

ruxolitinib 6Hydroxyurea 3fludarabine phosphate 2bomedemstat 2Whole-Body Irradiation 2Tacrolimus 2Specimen Handling 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Injections 2Cyclophosphamide 2Busulfan 2Biopsy 2Azacitidine 2venetoclax 1veliparib 1umbralisib 1piperine 1pevonedistat 1iadademstat 1givinostat hydrochloride 1givinostat 1fludarabine 1fedratinib 1demethoxycurcumin 1decitabine and cedazuridine drug combination 1Transplantation 1Topotecan 1Stem Cell Transplantation 1Sirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Polycythemia Vera × iadademstat × 90 days × Clear all
NCT06661915 2026-05-29

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Suspended
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡